RGNXREGENXBIO Inc.

$8.08-23% 1Y

Is the price fair?

What RGNX's price assumes

REGENXBIO Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 5.00× revenue.

5.00

Price / sales · no P/E: the last twelve months did not end in a profit

Price / book
20.8

Price / book · as of 2026-Q1

Details›
Price / bookas of 2026-Q1
20.8
EV / EBIToperating margin −94%: the multiple describes the denominator
not meaningful
Market capitalisation
$418M

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.